- Report
- March 2024
- 185 Pages
Global
From €3242EUR$3,374USD£2,788GBP
€3602EUR$3,749USD£3,097GBP
- Report
- March 2024
- 187 Pages
Global
From €3242EUR$3,374USD£2,788GBP
€3602EUR$3,749USD£3,097GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,652GBP
- Report
- January 2024
- 182 Pages
Global
€4799EUR$4,995USD£4,127GBP
From €300EUR$334USD£267GBP
- Report
- June 2019
- 80 Pages
Global
From €1248EUR$1,299USD£1,073GBP
From €300EUR$334USD£267GBP
- Report
- April 2021
- 180 Pages
Global
From €2883EUR$3,000USD£2,479GBP
- Report
- May 2024
- 200 Pages
From €3988EUR$4,150USD£3,429GBP
- Drug Pipelines
- March 2020
- 255 Pages
Global
From €3363EUR$3,500USD£2,892GBP
- Drug Pipelines
- December 2019
- 66 Pages
Global
From €3363EUR$3,500USD£2,892GBP
From €114EUR$119USD£98GBP
- Book
- June 2020
- 198 Pages
- Report
- November 2021
- 747 Pages
Global
From €3843EUR$4,000USD£3,305GBP
- Book
- April 2021
- 464 Pages
Chemokines are a family of small proteins that are involved in the regulation of cell movement and communication. They are important in the immune system, as they are involved in the recruitment of immune cells to sites of infection or inflammation. In the biotechnology market, chemokines are used in the development of therapeutics for a variety of diseases, including cancer, autoimmune diseases, and infectious diseases.
Chemokines are also used in the development of diagnostics, such as biomarkers for disease progression and prognosis. Additionally, chemokines are used in the development of vaccines, as they can be used to target specific immune cells to the site of infection.
Companies in the chemokines market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more
